avatrombopag   Click here for help

GtoPdb Ligand ID: 9953

Synonyms: AKR-501 [1] | Doptelet® | E5501 [4] | YM477
Approved drug
avatrombopag is an approved drug (FDA (2018), EMA (2019))
Compound class: Synthetic organic
Comment: Avatrombopag is a second generation, small molecule, orally administered thrombopoietin receptor agonist [1]. It was discovered through its ability to mimic the action of endogenous thrombopoietin which is the primary physiological regulator of normal platelet production. The pharmacokinetics, pharmacodynamics, pharmacogenomics, safety, and tolerability of avatrombopag were reported by Nomoto et al. in 2017 [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 158.38
Molecular weight 648.15
XLogP 5.6
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1sc(c(n1)c1scc(c1)Cl)N1CCN(CC1)C1CCCCC1
Isomeric SMILES OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1sc(c(n1)c1scc(c1)Cl)N1CCN(CC1)C1CCCCC1
InChI InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38)
InChI Key OFZJKCQENFPZBH-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Avatrombopag is approved by the FDA and EMA as a treatment for thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo elective surgery [3]. FDA approval was expanded in June 2019 to include treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have failed to respond effectively to a previous treatment.
Click here to link to the full list of avatrombopag studies that are registered with ClinicalTrials.gov.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Like thrombopoetin, avatrombopag dose-dependently stimulates differentiation of hematopoietic progenitor cells to megakaryocytes, and magakaryocyte polyploidization, which are actions that underlie platelet production [1].
External links Click here for help